-
Novo Nordisk launches oral Wegovy weight-loss treatment across US
THE WHAT? Novo Nordisk has begun broad US distribution of Wegovy pill, the first oral GLP-1 treatment approved for chronic weight management in adults with obesity or overweight with related medical conditions. THE DETAILS The once-daily oral formulation of semaglutide received FDA approval on December 22, 2025 and is now available through more than…
-
FDA Approves Oral Wegovy, the First Daily GLP-1 Pill
Novo Nordisk marks a turning point in obesity care.